Siltuximab for antibody-mediated rejection after lung transplant
A Phase 1 Clinical Trial of Siltuximab for the Treatment of Antibody-Mediated Rejection after Lung Transplantation
['FUNDING_OTHER'] · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · NIH-11394141
This trial gives siltuximab to people with antibody-mediated rejection after a lung transplant to try to control the immune response harming the new lung.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH (nih funded) |
| Locations | 1 site (SALT LAKE CITY, UNITED STATES) |
| Trial ID | NIH-11394141 on ClinicalTrials.gov |
What this research studies
You would be offered a Phase 1 trial of siltuximab, a drug that blocks the inflammatory protein IL-6, for antibody-mediated rejection (AMR) after a lung transplant. The study begins with small doses to check safety, side effects, and to identify an appropriate dose. You would have regular blood tests to track donor-specific antibodies and immune markers, lung function tests, and clinical monitoring for rejection or infection. If the drug calms the immune attack, it may help protect your transplanted lung and slow progression to chronic lung allograft dysfunction.
Who could benefit from this research
Good fit: Adults who have received a lung transplant and are diagnosed with antibody-mediated rejection, including evidence of donor-specific HLA antibodies and clinical signs of graft injury, are the intended participants.
Not a fit: People without antibody-mediated rejection, those with longstanding irreversible chronic lung allograft dysfunction, or those with uncontrolled serious infections are unlikely to benefit from this trial.
Why it matters
Potential benefit: If successful, siltuximab could reduce immune-driven injury after AMR and help improve short- and long-term survival of lung transplants.
How similar studies have performed: Blocking IL-6 has shown promise in other transplant and immune settings and in small case series, but using siltuximab for lung transplant AMR is novel and not yet proven in randomized trials.
Where this research is happening
SALT LAKE CITY, UNITED STATES
- UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH — SALT LAKE CITY, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: HACHEM, RAMSEY — UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH
- Study coordinator: HACHEM, RAMSEY
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.